Intrauterine growth retardation: pathophysiology and possibilities for intrauterine treatment

M P Johnson1, M I Evans

  • 1Department of Obstetrics and Gynecology, Hutzel Hospital/Wayne State University, Detroit, Mich.

Fetal Therapy
|January 1, 1987
PubMed

Insights

Understanding intrauterine growth retardation (IUGR) pathophysiology is key to developing targeted therapies. Advances in obstetrics have reduced perinatal risks, but IUGR remains a significant concern requiring specific treatments.

Area of Science:

  • Obstetrics and Perinatal Medicine
  • Fetal Development Research
  • Neonatal Health Studies

Background:

  • Perinatal morbidity and mortality have significantly decreased due to advancements in obstetrical care.
  • Intrauterine growth retardation (IUGR) remains a critical factor contributing to remaining perinatal complications.
  • Current therapeutic approaches for IUGR are largely empirical.

Purpose of the Study:

  • To review the current understanding of intrauterine growth retardation (IUGR) pathophysiology.
  • To explore the potential for developing specific, pathophysiology-based therapies for IUGR.
  • To identify novel treatment strategies beyond current empirical methods.

Main Methods:

  • Literature review of IUGR pathophysiology.
  • Analysis of existing research on IUGR subtypes.
  • Exploration of potential therapeutic interventions based on pathophysiological understanding.

Main Results:

  • Different types of IUGR have distinct pathophysiological mechanisms.
  • Understanding these mechanisms opens avenues for targeted therapeutic interventions.
  • Potential therapies include hyperbaric oxygen and specific nutritional supplementation.

Conclusions:

  • A deeper understanding of IUGR pathophysiology is essential for advancing treatment.
  • Specific therapies tailored to IUGR subtypes hold promise for improving outcomes.
  • Future research should focus on developing and validating these targeted treatments.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...